Implantica’s RefluxStop[TM] health economic research, showing superior cost-effectiveness, has received top-recognition at ISPOR, the world’s leading European Health-Economics Conference
Implantica AG (publ.), a medtech company at the forefront of bringing advanced technology into the body, presented an abstract on cost-effectiveness analysis in Sweden, which was recognized among the Top 5% Posters category for its high scientific quality at the ISPOR Europe conference 2023 (International Society for Pharmacoeconomics and Outcomes Research) in Copenhagen, Denmark.The in-depth and comprehensive health economic analyses in Sweden and Switzerland including four successful abstracts demonstrates that RefluxStop™ is more cost-effective against existing treatment options. The